Contemporary Management of HIV 2019

Expert faculty review key data informing the optimal use of contemporary HIV treatment across settings, including first-line treatment, ART modification in virologically suppressed patients or those experiencing virologic failure, and new and emerging ART strategies.
Eric S. Daar, MD
Daniel R. Kuritzkes, MD
David A. Wohl, MD

Downloadable Slidesets

Download this expert-authored slideset to review key data on emerging ART strategies, including rapid ART initiation, dual therapy, and long-acting antiretrovirals. (Updated September 2, 2019 with data from IAS 2019)

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: January 30, 2019

Download this expert-authored slideset to review key data from CROI 2019 on a wide range of HIV topics, including new approaches to PrEP, treating HIV in women and during pregnancy, INSTIs for switch/maintenance therapy, complications of HIV and/or ART, and novel therapeutic agents.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: May 10, 2019

In this downloadable slideset, review key HIV data from IAS 2019 on the updated NTD risk in women receiving ART at conception, PrEP, first-line and switch options, and early-phase investigational strategies.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Released: August 15, 2019

In this downloadable slideset, review key HIV data from the 2019 IDWeek and EACS meetings on PrEP outcomes, ART efficacy and tolerability in first-line and switch settings, metabolic and weight considerations with HIV therapy, and regimen selection during pregnancy.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
David A. Wohl, MD
Released: December 5, 2019

Download this expert-authored slideset to review key data on optimizing the use of current ART regimens, including starting ART, modifying ART after stable virologic suppression, and key considerations for persons with HIV with long-term experience on ART. (Updated September 2, 2019 with new data from IAS 2019)

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Released: March 8, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue